Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention
Year: 2014
Type: article
Abstract: The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two decades ago helped set in motion an avalanche of research exploring how genomic information can be optimally applied to identify and clinically care for individuals with a high risk of developing cancer. Genetic testing for mutations in BRCA1, BRCA2, and other breast cancer susceptibility genes has since proved to be a valuable tool for determining eligibility for enhanced screening and prevention strategies, as well as for identifying patients most likely to benefit from a targeted therapy. Here, we discuss the landscape of inherited mutations and sequence variants in BRCA1 and BRCA2, the complexities of determining disease risk when the pathogenicity of sequence variants is uncertain, and current strategies for clinical management of women who carry BRCA1/2 mutations.
Source: Science
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: green
Funder: National Cancer Institute
Awards: Genotype and phenotype predictors in therapy response in renal cell carcinoma, A genome-wide association study for breast cancer in BRCA1 mutation carriers, Post genome wide association studies in testicular germ cell tumors, G2731186574, G3428346584, BRCA2 missense mutations and breast cancer, G431899019, G669821179, G704544610, BRCA1 and BRCA2 missense mutations and breast cancer risk, Cancer Center Support Grant, Mayo Clinic Breast Cancer SPORE, Abramson Cancer Center Support Grant
OpenAlex ID: W2162956417